Bladder cancer · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Gemcitabine and RT Variant #01 | — | R 8 361 | 28d | — | ~15.7 mo | ~1 | ~R 8 361 PFS proxy · indirect | 2 |
Cisplatin and Paclitaxel (TP) and RT Variant #01 | — | R 2 425 | 21d | — | — | ~1 | ~R 2 425 PFS proxy · indirect | 1 |
Cisplatin and Fluorouracil (CF) and RT Variant #01 | — | R 1 774 | 17d | ~16.0 mo | ~17.0 mo | ~1 | ~R 1 774 PFS proxy · indirect | 6 |
Paclitaxel and RT Variant #01 | — | R 1 714 | — | — | — | ~1 | ~R 1 714 indirect | — |
Cisplatin and RT Variant #01 | — | R 588 | 49d | ~16.6 mo | ~58.6 mo | ~1 | ~R 588 PFS proxy · indirect | 22 |
5 of 5 regimens shown